Critical Care Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles - GBI Research Reports

Critical Care Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles

Critical Care Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles - GBI Research Reports
Critical Care Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles
Published Sep 17, 2011
87 pages — Published Sep 17, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research's report, Critical Care Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles provides in-depth analysis of drivers and barriers that impact the global critical care market. The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain), and Japan. This includes treatment usage patterns, average annual cost of therapy and market size forecast until 2017 for the key geographies as well as the leading therapeutic segments. The report also provides information on the R&D product pipeline and explores the competitive landscape, including major players in the critical care market. Finally, the report includes analysis on mergers and acquisitions (M&As) in the critical care market. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Researchs team of industry experts.

Scope

- Data and analysis on the critical care market in the leading geographies of the world the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the critical care market that includes markets for factor XIII concentrate, fibrinogen concentrate, antithrombin, prothrombin complex concentrate and albumin from 2002 to 2010, with forecasts to 2017
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, cost of therapy, sales volume and treatment usage patterns such as disease population, diagnosis population and prescription population
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the global critical care market, including top companies benchmarking. The key companies studied in this report are CSL, Octapharma, Baxter, Grifols and LFB
- Key M&A activities that took place in 2010 and 2011 in the critical care market

Reasons to buy

- Align your product portfolio to the markets with high growth potential
- Build effective strategies to launch their pipeline products by identifying potential geographies
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps
- Develop key strategic initiatives by studying the key strategies of top competitors
- Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication
- Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious

  
Source:
Document ID
GBIHC170MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents45
  List of Tables62
  List of Figures81
Critical Care Market to 2017 Introduction91
  GBI Research Report Guidance91
Critical Care Market to 2017 Global Overview102
Critical Care Market to 2017 Geographical Landscape125
  Introduction121
  The US131
    Revenue131
  Top Five Countries of Europe141
    Revenue142
  Japan161
    Revenue161
Critical Care Market to 2017 Therapeutic Landscape1753
  Factor XIII Concentrate171
    Introduction171
    Revenue183
    Geographical Segmentation211
    Cost of Treatment222
    Treatment Usage Pattern241
      Diseased Population251
      Diagnosed Population251
  Drivers and Restraints251
    Drivers261
      Anticipated Launch of rFXIII will Drive the Market in Future261
      Better Safety and Efficacy as Compared to Other Human Derived Blood Products261
    Restraint261
      Lack of Robust Data on the Use of Factor XIII Concentrates in High Risk Surgical Settings261
  Marketed Products271
    Fibrogammin P / Corifact271
      Product Description271
      Mechanism of Action271
  Antithrombin (AT) Market271
    Introduction272
    Revenue292
    Geographical Segmentation311
    Cost of Treatment321
    Treatment Usage Pattern331
      Diseased Population341
      Diagnosed Population341
      Patients on AT Concentrates351
  Drivers and Restraints351
    Drivers361
      Better Safety and Efficacy of AT Concentrate will Increase the Uptake in the Forecast Period361
      Launch of Atryn will Drive the AT Concentrate Market361
    Restraints361
      Lack of Robust Scientific Evidence about Usefulness of AT Concentrates361
      Comparatively High Cost of Therapy with AT Concentrates361
  Marketed Products371
    Thrombate III (Antithrombin III human)371
      Product Description371
      Mechanism of Action371
    Anbinex (Grifols SA)371
    Kybernin (CSL Behring GmbH)381
    Aclotine (Laboratory of French Split and Biotechnology)381
    ANTITHROMBIN III (Baxter)381
    Neuart (Mitsubishi Tanabe Pharma Corporation)391
    Atryn391
      Product Description391
      Mechanism of Action391
  Fibrinogen Concentrate Market401
    Introduction401
    Revenue411
    Geographical Segmentation423
    Cost of Treatment451
    Treatment Usage Pattern461
      Diseased Population461
      Diagnosed Population461
      Patients on Fibrinogen Concentrate462
  Drivers and Restraints481
    Drivers481
      Increasing Uptake of Fibrinogen Concentrates481
    Barriers481
      Lack of Robust Data on Use of Factor Concentrates481
  Marketed Products491
    Haemocomplettan/Riastap491
      Product Description491
      Mechanism of Action491
  Albumin501
    Introduction501
    Revenue512
    Geographical Segmentation531
    Cost of Treatment542
    Treatment Usage Pattern561
  Drivers and Restraints571
    Drivers571
      Increasing Cost and Therapeutic Uses of Albumin will Drive the Growth of the Albumin Market571
    Restraints571
      Lack of Clinical Data for Use of Human Albumin in Various Clinical Settings will Restrict Growth of the Albumin Market571
      Relatively High Price of Human Albumin May Act as a Barrier for the Global Albumin Market in Upcoming Years581
  Marketed Products581
    Albuminar (CSL Behring)581
    Human Albumin Biotest, solution for infusion (Biotest)581
    Buminate 25% (Baxter)591
    Human Albumin Grifols 25% (Grifols SA)591
  Prothrombin Complex Concentrate Market (PCC)591
    Introduction591
      Oral Anticoagulant Reversal601
      Other Indications601
    Revenue612
    Revenue Breakup631
    Geographical Segmentation641
    Cost of Treatment651
    Treatment Usage Pattern661
  Drivers and Restraints671
    Drivers671
      Preference for PCC as Compared to Other Alternatives will Drive the Growth of the PCC Market in the Forecast Period671
      Increased use of PCC for Various Bleeding Complications681
    Barriers681
      Lack of Clinical Data for the use of PCC in Various Possible Indications is Restraining the Growth of the PCC Market681
  Marketed Products681
    Beriplex P/N681
      Product Description681
      Mechanism of Action681
    Feiba691
      Product Description691
      Mechanism of Action691
Critical Care Market to 2017 - Product Pipeline703
  Introduction702
    rFXIII (Novo Nordisk A/S)721
Critical Care Market to 2017 Competitive Landscape737
  CSL Limited731
    Company Overview731
    SWOT Analysis741
  Octapharma AG741
    Company Overview741
    SWOT Analysis751
  Baxter International Inc.761
    SWOT Analysis761
  Grifols SA (Grifols)771
    Company Overview771
    SWOT Analysis781
  LFB S.A. (LFB)791
    Company Overview791
    SWOT Analysis791
Critical Care Market to 2017 Mergers &Acquisitions Landscape801
  LFB Biotechnologies Completes Acquisition of GTC Biotherapeutics801
  Grifols Completes Acquisition of Talecris Biotherapeutics801
Critical Care Market to 2017 Appendix817
  Market Definitions811
  Abbreviations811
  Research Methodology822
    Coverage821
    Secondary Research821
    Primary Research831
  Therapeutic Landscape833
    Epidemiology-based Forecasting842
  Geographical Landscape861
  Pipeline Analysis861
  Competitive Landscape861
    Expert Panel Validation861
  Contact Us861
  Disclaimer861
  Sources871

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Critical Care Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles" Sep 17, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Critical-Care-Market-to-2017-Shift-of-Focus-towards-PCC-Factor-Concentrates-and-Antithrombins-due-to-Better-Safety-and-Efficacy-Profiles-2115-261>
  
APA:
GBI Research Reports. (2011). Critical Care Market to 2017 - Shift of Focus towards PCC, Factor Concentrates and Antithrombins due to Better Safety and Efficacy Profiles Sep 17, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Critical-Care-Market-to-2017-Shift-of-Focus-towards-PCC-Factor-Concentrates-and-Antithrombins-due-to-Better-Safety-and-Efficacy-Profiles-2115-261>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.